Details for Patent: 9,603,853

Which drugs does patent 9,603,853 protect, and when does it expire?

Patent 9,603,853 protects QELBREE and is included in one NDA.

This patent has seventeen patent family members in seven countries.

Summary for Patent: 9,603,853

Title:	Formulations of viloxazine
Abstract:	Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
Inventor(s):	Michael L. Vieira, Austin B. Huang, Padmanabh P. Bhatt
Assignee:	Supernus Pharmaceuticals Inc
Application Number:	US15/157,549
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,603,853
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

US Patent 9,603,853: Viloxazine Extended-Release Formulation Claims, Expiration, and Patent Landscape

US Patent 9,603,853 protects a specific viloxazine multiparticulate formulation and its use to treat ADHD or major depressive disorder. The patent does not broadly cover every viloxazine product. Its independent claim requires a combination of immediate-release and extended-release pellets, defined coating materials, a specified release-controller-to-pore-former ratio, a defined viloxazine loading, and a dissolution profile. The patent is assigned to Supernus Pharmaceuticals and is relevant to Qelbree, the company’s once-daily viloxazine extended-release product.

The patent’s projected expiration is November 5, 2032, subject to any patent-term adjustment or terminal-disclaimer effects recorded in the USPTO file. It sits within a broader Supernus patent estate covering viloxazine formulations, dosing, pharmacokinetics, and methods of treating ADHD.

What does US Patent 9,603,853 protect?

US 9,603,853 protects a method of treating ADHD or major depressive disorder using a formulation that combines immediate-release and extended-release viloxazine components.

The formulation must contain:

1. An immediate-release component with an inert core and a viloxazine-containing layer.
2. An extended-release component with:
   • an inert core;
   • a viloxazine-containing first layer; and
   • an outer layer containing a release-rate-controlling compound and a pore former.
3. A release-controller-to-pore-former weight ratio of 19:1 to 8.5:1.5.
4. A release-rate-controlling compound representing 5% to 65% of the XR component.
5. Total viloxazine representing 25% to 75% of the formulation by weight.
6. At least 80% release of viloxazine or its salt over at least two hours in vitro.

The claim is therefore a formulation-plus-method claim. A product that contains viloxazine but lacks the required IR/XR pellet architecture or coating ratio would not fall within claim 1 solely because it is extended release.

How does claim 1 of US 9,603,853 operate?

Claim 1 uses a multiparticulate drug-delivery design. The IR component provides an initial release of viloxazine. The XR component releases additional viloxazine over time through a coated pellet structure.

The XR coating has two legally important elements:

Claim element	Required limitation
Core	Inert core
Drug layer	Viloxazine, with optional pharmaceutical excipient
Outer layer	Release-rate-controlling compound plus pore former
Ratio	Release controller to pore former from 19:1 to 8.5:1.5
Controller loading	5% to 65% of XR component
Pore former	Povidone, hypromellose, hydroxyethyl cellulose, hydroxypropyl cellulose, or organic acid
Total drug loading	25% to 75% of the total formulation
Dissolution	At least 80% released over at least two hours in vitro
Therapeutic use	ADHD or major depressive disorder

The claim lists numerous possible release-rate-controlling materials, including ethylcellulose, cellulose acetate, waxes, hydrogenated vegetable oils, glyceryl behenate, glyceryl palmitostearate, PEG glyceryl esters, methacrylate copolymers, polyvinyl acetate, cellulose acetate propionate, and combinations.

The claim is broad as to the identity of the controller but narrower as to the formulation architecture and composition ranges.

What do dependent claims 2 through 14 add?

The dependent claims narrow the protected method by specifying disease, dosing, patient population, clinical outcomes, and pharmacokinetics.

Claims	Added limitation
2	ADHD treatment
3	Once-daily administration
4	Twice-daily administration
5	Reduced side effects versus the same IR viloxazine dose given BID or TID
6	Gastrointestinal or neurological side effects
7	Dyspepsia, nausea, or vomiting
8-9	Sleep disturbance, including insomnia
10	Human child
11	Human adult
12	Daily dose of 10 mg to 800 mg
13	Steady-state Cmax at 50% to 125% of IR BID/TID Cmax and above the minimum therapeutic concentration
14	AUCtau at 80% to 125% of IR BID/TID exposure

Claims 3, 5, 13, and 14 are commercially significant because they connect the formulation to the intended once-daily pharmacokinetic profile. Claims 5 through 9 are harder to evaluate from a product label alone because they depend on comparative clinical or pharmacological evidence.

What patents protect Qelbree and viloxazine extended release?

Qelbree is viloxazine hydrochloride extended release. Supernus has developed a patent portfolio around the product rather than relying on one formulation patent.

The principal patent categories are:

Patent category	Protected subject matter	Commercial relevance
Pellet formulation	IR and XR viloxazine components, coated multiparticulates, release-control materials	Directly relevant to Qelbree dosage forms
Release profile	Drug release over defined time periods	Supports product differentiation from IR viloxazine
Pharmacokinetics	Cmax and AUC relationships versus IR dosing	Supports once-daily use
Methods of treatment	ADHD and major depressive disorder	Supports labeled and potential off-label use
Dosing	Pediatric and adult dosing ranges	Supports commercial presentations and labeling
Manufacturing	Layering, coating, and multiparticulate production processes	Can create non-formulation barriers to generic entry

Public FDA Orange Book records have identified US 9,603,853 among the patents associated with Qelbree, together with later Supernus patents covering related aspects of viloxazine extended release. Orange Book listings should be distinguished from the full family of US and foreign patents because the FDA list is limited to patents submitted for the approved drug and its approved use or formulation. (FDA, 2024a)

When does US Patent 9,603,853 lose exclusivity?

The projected patent expiration date is November 5, 2032. The date follows the 20-year patent term measured from the relevant nonprovisional filing date, subject to any USPTO-recorded patent-term adjustment. The issued patent was granted on March 28, 2017. (USPTO, 2017)

Regulatory exclusivity is shorter:

Exclusivity or protection	Date or period
Qelbree FDA approval	April 26, 2021
New chemical entity exclusivity	Five years from approval, subject to statutory Paragraph IV timing
Pediatric exclusivity	Six-month extension if granted and applicable
Projected patent expiration for US 9,603,853	November 5, 2032

Qelbree was approved for ADHD in pediatric patients aged 6 to 17 in 2021 and for adults in 2022. FDA approval does not itself establish that every patent claim in the Supernus portfolio is valid or infringed. It establishes the regulatory status of the product and its listed protection. (FDA, 2021; FDA, 2022)

What is the Orange Book status of Qelbree?

Qelbree is an FDA-approved prescription product marketed by Supernus Pharmaceuticals. Its active ingredient is viloxazine hydrochloride in an extended-release formulation. The product is approved for ADHD in patients six years of age and older.

The Orange Book is important for generic entry because an ANDA applicant must address listed patents through certification, including a Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed. The patent listing does not prevent a generic applicant from challenging the patent. It requires the applicant to make a statutory certification and triggers potential notice and litigation procedures.

For US 9,603,853, the commercial risk is strongest where a proposed generic uses:

• the same or substantially similar IR/XR multiparticulate design;
• a viloxazine drug layer on inert cores;
• a polymeric or wax-based release-control coating;
• a pore former within the claimed list;
• the claimed coating ratio;
• the claimed viloxazine loading; and
• a dissolution profile meeting the claim.

A generic applicant may seek to design around one or more of these limitations rather than challenge the patent directly.

Which companies are challenging Qelbree patents?

Publicly available information through June 2024 did not establish a final court judgment invalidating US 9,603,853 or a publicly adjudicated Paragraph IV challenge to that patent. The absence of a reported judgment does not establish that no ANDA filing or confidential patent certification exists.

Generic applicants can challenge Qelbree through several routes:

1. Paragraph IV certification against an Orange Book-listed patent.
2. A non-infringement position based on a different pellet structure or coating composition.
3. A validity challenge based on anticipation, obviousness, written description, enablement, or indefiniteness.
4. A section viii statement that the applicant will omit a patented method of use, where legally available.
5. A formulation redesign that avoids the claimed ratio, loading, or dissolution limitations.

The most vulnerable portions of claim 1 are likely to be the interaction among the coating ratio, controller loading, total drug loading, and dissolution requirement. A challenger would typically assess prior art on viloxazine multiparticulates, ethylcellulose or methacrylate coatings, pore-former systems, and mixed IR/XR delivery.

How strong is the patent estate for viloxazine extended release?

The estate has meaningful commercial strength because US 9,603,853 combines several limitations in one claim. A generic cannot necessarily avoid infringement by changing only the dosage frequency. It may still infringe claim 1 if the formulation meets the structural and dissolution requirements.

The estate’s strength is reduced by the claim’s technical specificity. Potential pressure points include:

• Whether the accused product contains separate IR and XR components.
• Whether each component has the required core-and-layer structure.
• Whether the XR outer layer satisfies the ratio mathematically.
• Whether the release-rate controller falls within the listed materials.
• Whether the controller is present at 5% to 65% of the XR component.
• Whether the 80% release limitation is met under the claimed in-vitro test.
• Whether the accused formulation is used for a claimed disease or method.

The method-of-treatment limitations also create enforcement issues. Direct infringement generally requires performance of the claimed treatment method. In an ANDA case, the proposed label, formulation, and intended use become central to induced-infringement and declaratory-judgment analysis.

What formulation patents protect Qelbree against generic entry?

The formulation patents are more relevant to Qelbree than broad compound patents because viloxazine itself is an old active pharmaceutical ingredient. The original IR drug was marketed in Europe decades ago, reducing the likelihood that Supernus could rely on a broad composition-of-matter patent for viloxazine.

The key barriers are therefore:

• the specific extended-release dosage form;
• the mixed IR/XR delivery profile;
• pellet coating technology;
• once-daily pharmacokinetics;
• pediatric and adult treatment methods;
• manufacturing methods; and
• Orange Book-listed patents with expiration dates extending beyond regulatory exclusivity.

A generic applicant could potentially market a different viloxazine formulation after regulatory exclusivity ends if it avoids listed patent claims and obtains FDA approval. A successful Paragraph IV challenge could accelerate entry, while a settlement could defer launch to an agreed date.

What litigation and settlement risks affect Qelbree?

Patent litigation risk depends on whether an ANDA filer targets the listed patents before their expiration. A suit filed within the statutory period can trigger a 30-month stay of FDA approval, subject to court decisions and statutory exceptions. The stay does not necessarily prevent all forms of commercial activity and does not determine patent validity.

No publicly established settlement date for US 9,603,853 is identified in the cited sources. Settlement terms in pharmaceutical patent cases may include an authorized generic arrangement, a delayed generic launch date, a license, or restrictions on the challenged formulation. Such terms may remain confidential or appear only in court filings, FTC reviews, or later regulatory records.

What generic launch scenarios exist for viloxazine?

Three launch scenarios are commercially plausible:

Scenario	Result
No Paragraph IV challenge	Generic entry generally waits for patent and regulatory barriers to expire
Paragraph IV challenge unsuccessful	Entry is delayed until the asserted patent claims expire or become unavailable
Paragraph IV challenge successful	Earlier entry is possible, subject to other listed patents and regulatory exclusivity
Design-around formulation	A generic may enter with a different release technology if it avoids the listed claims
Settlement	Entry occurs on a negotiated date, potentially with licensing or other restrictions

The practical launch date will be controlled by the entire Qelbree patent and exclusivity portfolio, not by US 9,603,853 alone. A generic that avoids this patent may still face later Supernus patents listed for the same product.

How does Qelbree compare with competing ADHD therapies?

Qelbree competes with stimulant and nonstimulant ADHD products. Its main nonstimulant comparators include atomoxetine, extended-release guanfacine, and extended-release clonidine. Stimulant competitors include methylphenidate and amphetamine products.

Product class	Active ingredient	Patent landscape	Commercial distinction
Qelbree	Viloxazine hydrochloride ER	Formulation and method patents	Nonstimulant, once-daily ADHD treatment
Strattera	Atomoxetine	Mature generic market	Nonstimulant comparator
Intuniv	Guanfacine ER	Mature generic market	Nonstimulant alpha-2A agonist
Kapvay	Clonidine ER	Mature generic market	Alpha-2 agonist
Concerta and related products	Methylphenidate ER	Complex formulation and device history	Stimulant
Adderall XR and related products	Amphetamine salts ER	Mature and continuing formulation disputes	Stimulant

Qelbree’s patent value depends on maintaining a differentiated extended-release profile while protecting the formulation from substitution by a generic viloxazine product.

What is the revenue exposure from US 9,603,853?

The patent protects a product line rather than a standalone revenue stream. Exposure depends on Qelbree’s US sales, the proportion of prescriptions filled with the listed formulation, payer coverage, and the timing of generic competition.

A generic launch before November 2032 could reduce net sales through price erosion, formulary substitution, and loss of market exclusivity. The magnitude would depend on whether the entrant is an authorized generic, a single ANDA product, or multiple competing generics.

Supernus’s public filings identify Qelbree as a commercial growth product but do not allocate all future revenue specifically to US 9,603,853. Revenue risk should therefore be modeled against the full Qelbree patent estate and not assigned solely to this patent. (Supernus Pharmaceuticals, 2024)

Key Takeaways

• US 9,603,853 is a method patent covering treatment of ADHD or major depressive disorder with a mixed IR/XR viloxazine multiparticulate formulation.
• Claim 1 requires specific pellet architecture, coating materials, controller-to-pore-former ratios, drug loading, and release performance.
• The patent is relevant to Qelbree but does not broadly cover every viloxazine formulation.
• The projected expiration date is November 5, 2032, subject to USPTO term adjustments or disclaimers.
• Qelbree’s FDA regulatory exclusivity ends materially earlier than the patent term.
• Generic entry may occur through a Paragraph IV challenge, a design-around formulation, settlement, or expiration of the relevant patent portfolio.
• The main technical vulnerability is the specificity of the formulation limitations, particularly the coating ratio and dissolution requirement.
• Commercial protection depends on US 9,603,853 together with later Qelbree formulation, pharmacokinetic, dosing, and method patents.

FAQs About US Patent 9,603,853 and Qelbree

Does US 9,603,853 cover viloxazine hydrochloride itself?

No. The patent claims a formulation used in a treatment method. It does not broadly claim viloxazine hydrochloride as a chemical compound.

Does once-daily Qelbree necessarily infringe US 9,603,853?

Not automatically. Once-daily dosing is recited in dependent claim 3, but infringement also requires the formulation and method limitations in claim 1.

Can a generic viloxazine product avoid US 9,603,853?

Potentially. A generic may attempt to avoid the patent by using a different release architecture, coating ratio, pore former, drug loading, or dissolution profile. Other Qelbree patents may still apply.

Does the patent cover major depressive disorder?

Yes. Claim 1 expressly covers treating ADHD or major depressive disorder. The patent’s commercial relevance is currently stronger for ADHD because Qelbree’s FDA approval is for ADHD.

Is US 9,603,853 still enforceable after FDA exclusivity expires?

Yes, unless it expires, is invalidated, is held unenforceable, or is otherwise limited. FDA regulatory exclusivity and patent enforceability are separate forms of protection.

References

1. U.S. Food and Drug Administration. (2021). FDA approves novel treatment for attention deficit hyperactivity disorder in children. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-attention-deficit-hyperactivity-disorder-children

2. U.S. Food and Drug Administration. (2022). Qelbree prescribing information. https://www.accessdata.fda.gov

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,603,853, Pharmaceutical compositions and methods of use thereof. https://patents.google.com/patent/US9603853B2

5. Supernus Pharmaceuticals, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission. https://www.sec.gov/edgar.shtml

Drugs Protected by US Patent 9,603,853

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No	9,603,853					FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-002	Apr 2, 2021		RX	Yes	No	9,603,853					FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-003	Apr 2, 2021		RX	Yes	Yes	9,603,853					FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

International Family Members for US Patent 9,603,853

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013217013
Australia	2017206245
Australia	2019216707
Australia	2020233746
Canada	2864088